博雅生物: 董事会决议公告

Core Viewpoint - The board of directors of China Resources Boya Bio-Pharmaceutical Group Co., Ltd. held its 15th meeting of the 8th session, approving the 2025 semi-annual report and various proposals, including profit distribution and organizational restructuring [1][2][3]. Board Meeting Details - The board meeting was held on August 21, 2025, with all 7 participating directors present, and it complied with relevant laws and regulations [1]. - The meeting was chaired by Chairman Qiu Kai, with the presence of supervisors and senior management [1]. Financial Report Approval - The board approved the 2025 semi-annual report, confirming it accurately reflects the company's financial status and operational results without any misleading statements or omissions [1][2]. Profit Distribution Plan - The profit distribution plan for the first half of 2025 was approved, proposing a cash dividend of 1.50 yuan per 10 shares (including tax) to all shareholders, based on 504,248,738 shares [2][3]. - The plan aligns with regulations regarding cash dividends for listed companies [2]. Fund Management Compliance - The board confirmed that the management of raised funds complies with relevant regulations, ensuring no violations or harm to shareholder interests [3]. Organizational Restructuring - The company plans to optimize its organizational structure to enhance operational efficiency and adapt to market changes [4]. - The board approved the proposal for organizational restructuring, which aims to improve resource allocation [4]. Board Member Changes - Resignations of board members Liang Xiaoming and Yu Xiaohui were acknowledged, and new candidates Lin Peng and Wang Yifei were proposed for election as non-independent directors [5][6]. - The board also approved the appointment of Pan Yuxuan as the new board secretary [8]. Upcoming Shareholder Meeting - A temporary shareholder meeting is scheduled for September 12, 2025, to review the approved proposals [8].